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Background: Driver mutations are positively selected during the evolution of cancers. The relative frequency of a
particular mutation within a gene is typically used as a criterion for identifying a driver mutation. However, driver
mutations may occur with relative infrequency at a particular site, but cluster within a region of the gene. When
analyzing across different cancers, particular mutation sites or mutations within a particular region of the gene may
be of relatively low frequency in some cancers, but still provide selective growth advantage.
Results: This paper presents a method that allows rapid and easy visualization of mutation data sets and
identification of potential gene mutation hotspot sites and/or regions. As an example, we identified hotspot
regions in the NFE2L2 gene that are potentially functionally relevant in endometrial cancer, but would be missed
using other analyses.
Conclusions: HotSpotter is a quick, easy-to-use visualization tool that delivers gene identities with associated
mutation locations and frequencies overlaid upon a large cancer mutation reference set. This allows the user to
identify potential driver mutations that are less frequent in a cancer or are localized in a hotspot region of relatively
infrequent mutations.
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Driver mutations provide a growth advantage for tumor
cells and have been positively selected during the evolu-
tion of a cancer [1]. When exploring the genetic under-
pinnings or searching for possible therapeutic targets in
cancer, it is very important to be able to identify poten-
tial driver mutations. Driver mutations are often distin-
guished from passenger mutations by determining the
difference in frequency at a particular location within a
gene that results in a functional alteration of the protein
product [2]. Driver mutations may be exhibited as
alterations (missense, deletion, insertion, termination,
etc.) that occur at a higher frequency within a particu-
lar region within a protein and/or as a high frequency
alteration starting at a specific amino acid site. Figure 1
demonstrates driver mutations that localize at specific
amino acid regions or sites.* Correspondence: swoodman@mdanderson.org
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article, unless otherwise stated.However, what is considered a significant mutation
frequency varies among approaches. Some approaches
use frequency within the cancer of interest, while others
use the frequency across cancers [2]. The difference in
these approaches is highlighted by the recent analysis of
the well-established activating BRAF hotspot missense
mutations resulting in alterations at the V600 amino acid
position in multiple tumor types [3,4]. The BRAF V600
hotspot mutation occurs with a frequency of ~45% in
melanoma and papillary thyroid cancer, and about ~10%
in colorectal cancer, and the same mutation is typically
observed in 0-4% of most other cancers. The use of
specific small molecule inhibitors of mutant BRAF in pa-
tients with tumors harboring a BRAF V600 mutation
has demonstrated that neither within, nor across, cancer
frequency is sufficient to determine the functional sig-
nificance of inhibiting “driver” mutations [5].
The HotSpotter method for identifying potential muta-
tion hotspot sites and/or regions is agnostic as to whether
mutation frequencies are within or across cancer types.
The method is easily adaptable to any reference database
of somatic mutations. For this application, version 66 ofd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Figure 1 Driver mutation amino acid sites and regions. The COSMIC dataset was used to identify the most frequent mutations for
well-characterized driver mutation sites/regions. The y-axis demarcates the names of genes and frequency of mutations within each gene. The x-axis
demarcates the amino acid position within the protein product for each mutation. The vertical position of the blue dots represents the frequency of an
amino acid alteration at a specific site. For illustrative purposes a few well-characterized mutant proteins are displayed, and a threshold of at least 10
samples with a specific amino acid aberration was employed. For the IDH1 protein, the R132 amino acid site is clearly the most aberrant (n = 5,557
entries) to the exclusion of any other site. The BRAF protein displays both a dominant site at V600 (n = 32,371 entries) within one of two relatively high
frequency mutation regions. Finally, the KIT protein demonstrates regions with relatively high frequencies of amino acid alterations.
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[6] containing 1,524,610 entries was chosen.
Resources such as the cBio Portal [7] or the UCSC
Cancer Genomics Browser [8] are excellent for reviewing
publicly available data sets such as the Cancer Genome
Atlas [9]. However, an easy-to-use application for deter-
mining potential mutation hotspot sites/regions from
one’s own or publicly available mutation data sets would
be of great value to both those with experience and
those less experienced in exploring genomics results.
This report summarizes the development and testing of
such an application, which we named HotSpotter. Hot-
Spotter allows users to:
1. easily visualize potential driver mutations, especially
if the specific mutation is less frequent in the sample
set being analyzed,
2. spot potential driver mutations that localize across a
region of a gene,3. easily filter samples with the threshold frequency
desired,
4. analyze tumor mutation data without absolute
dependence on a normal control, and
5. easily add one’s own or publicly available mutation
data to enrich either the test or reference database.
Results and discussion
To illustrate the strength of the HotSpotter method, we
used mutation calls derived from exome sequencing data
of 248 tumors previously published by the TCGA uterine
corpus endometrial cancer (UCEC) work group [10]. To
eliminate self-referential observations, a COSMIC data
set devoid of the TCGA UCEC endometrial cancer sam-
ples was employed as the reference mutation data set.
HotSpotter displayed the frequency of every mutation
call in the TCGA UCEC dataset relative to that in the
COSMIC dataset. Manual visualization of the results
quickly identifies the potential mutation hotspot sites
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potential hotspots appear as large orange dots. These
dots are intentionally larger than the smaller blue dots
representing all the mutation calls for the particular gene
in the COSMIC database, on which they are overlaid. This
overlaying of the two plots allows effective visualization of
the potential driver mutations.
Figure 2 shows how HotSpotter illustrated potential mu-
tation hotspot amino acid sites and/or regions derived
from the TCGA UCEC samples (The Tableau interface
can be downloaded at the following address: http://public.
tableausoftware.com/views/HotSpotter-TCGA_UCEC_
selected/Selectedgenes). The y-axis demarcates the
names of genes and the frequency of specific amino
acid alterations arising from specific mutations (here-
after, termed ‘mutations’) within each gene. The x-axis
demarcates the amino acid position within the inferred
protein product for each mutation.
In the first row of Figure 2, the frequency of individual
TP53 mutations within the TCGA UCEC sample set are
shown (orange dots). Clearly, one of the TP53 mutations
within the UCEC sample set falls within a region with a
high frequency of mutations within the COSMIC data-
base (three distinct mutations with approximately 500,
600 and 1300 entries, respectively, demarcated by the
red rectangle). The other highest frequency TP53 muta-
tion site within the TCGA UCEC dataset is also one of
the top TP53 mutation sites within COSMIC (Figure 2,
row one, red circle, 1225 entries).
Mutations of the PTEN gene were more widely dis-
persed throughout the gene than the TP53 mutations in
both the TCGA UCEC samples and the COSMIC samples.Figure 2 HotSpotter identification of potential mutation hotspot sites
names of genes and frequency of mutations within each gene. The x-axis d
mutation. Orange dots (intentionally large for quick visualization) and their
in the UCEC test set. Blue dots (intentionally smaller) and their vertical posi
COSMIC dataset. For non-substitution mutations, the first amino acid at whNotably, HotSpotter readily illustrates the two highest fre-
quency mutation sites within the TCGA UCEC sample set
to be among the highest frequency mutation sites in COS-
MIC (Figure 2, row two, red circles). The other high
frequency PTEN mutation in the TCGA UCEC sample set
appears to locate to a highly mutated region in PTEN, as
demonstrated by the presence of four closely grouped mu-
tations (Figure 2, row two, red rectangle).
HotSpotter shows mutations within the CTNNB1 and
NFE2L2 genes in the TCGA UCEC samples to have a
clear overlap with highly mutated regions within these
genes in COSMIC (Figure 2, rows 3–4, red boxes).
NFE2L2 mutations within the TCGA UCEC dataset
would not be considered “recurrent mutations”, as they
are present only between one to three times at any one
site. However, when superimposed on the visualization
of NFE2L2 mutations in COSMIC, there is clearly over-
lap in amino acid regions 23–48 and 71–86. Scrolling
over any specific mutation in HotSpotter (see Figure 2
inset) reveals additional information. In this particular
case, the pointer arrow overlies the NFE2L2 mutation
with the highest frequency (highest orange dot) in the
TCGA UCEC samples. The inset box reveals the gene’s
name, amino acid position, source, and count of position
(i.e., the number of samples with mutations at that spe-
cific position). With this method, any one mutation or
set of mutations can be selected and the extensive
underlying data can be explored further by clicking on
the data set icon (Additional file 1: Figure S1A and B).
The underlying data shows that each of the NFE2L2 mu-
tation sites in endometrial cancer is also a mutation site
in a variety of other cancers, primarily in squamous cell/regions in the TCGA UCEC data set. The y-axis demarcates the
emarcates the amino acid position within the protein product for each
vertical position represent the frequency of mutation at a specific site
tion represent the frequency of mutations at specific sites in the
ich the alteration occurs is used as the “position”.
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identified by Sasaki et al. [11], who showed that muta-
tions in those regions were associated with significantly
worse prognosis in lung squamous cell carcinoma. Of
interest, these NFE2L2 mutation regions observed by the
HotSpotter method were not noted in the recently pub-
lished TCGA report on the genomic characterization of
UCEC [10]. Similarly, low-frequency mutations in DDHD1,
HNF1A and CHEK2 within endometrial cancer samples
were shown to be highly mutated sites/regions in multiple
cancers in the COSMIC database (Figure 2, rows 5–8, black
circles/box).
Conclusions
HotSpotter offers a rapid, easy-to-use method for ana-
lyzing one’s own and/or publicly available mutation data
sets (as shown with the TCGA UCEC data set). This ap-
proach is, of course, limited by the particular features of
the reference mutation data set employed, e.g. inclusion
of cell lines and tissues, over- and under- representation
of cancer types, the lack of a definitive sample denomin-
ator for many mutations, and redundancy of samples,
etc. However, a strength of HotSpotter is its flexibility; it
is agnostic to the particular methods that precede its use
(e.g., mutation calling algorithms, false discovery rates,
etc.). Essentially the same approach taken here can be
used with most reference databases, other than COS-
MIC. HotSpotter provides a very quick tool delivering
gene identities with associated mutation locations and
frequencies overlaid upon a cancer mutation reference
set (>1.5 million mutation calls in the example given).
The viewer can rapidly see specific gene mutation sites
and/or region patterns, and ready access to structured
underlying data is also provided, upon which further
analyses can be performed.
Methods
The Tableau Desktop business intelligence software [12]
was employed to create an interface that displays the
frequency/location of particular amino acid alterations
derived from gene mutations identified within the TCGA
UCEC sample set overlaid upon the frequency/location
of particular amino acid alterations derived from muta-
tions within the same gene within the COSMIC database
version 66 [6].
The following process was used to prepare a modified
COSMIC reference dataset. The amino acid mutation
position data was extracted from the “Mutation AA” col-
umn of the COSMIC data set for every mutation and
appended to the COSMIC data table as a new column
entitled “Position”. Another new column which must be
appended to the COSMIC data table is the column
entitled “Source”. The term ‘COSMIC’ was used for each
cell of the Source column for this analysis. After performingthese steps, the user can replace the COSMIC dataset with
any dataset of their choosing.
For the sample mutation dataset (TCGA UCEC), the
same steps used for the modified COSMIC reference
dataset must be performed. In addition, the rows of the
sample mutation dataset to be analyzed must be appended
to the modified reference dataset. Mandatory columns for
the reference and the sample data sets are the following:
“Gene name”, “Mutation AA”, “Position”, and “Source”.
The data table can contain additional columns, and the
position of the columns has no effect on the interface. The
only requirement is to have a table that contains the refer-
ence/sample mutations, and the table must have the four
columns as described above. To be able to differentiate
between the reference and the sample dataset, distinct
names in the “Source” column are necessary. The modi-
fied dataset can be easily updated in Tableau using the
“Edit connection” (Data menu - > [Reference dataset] - >
Edit Connection) menu item.
Additional file
Additional file 1: Figure S1. A) Highlighting mutation calls that arise
within two specific regions of the NFE2L2 gene from the TCGA UCEC
and COSMIC datasets. The underlying data for the selected NFE2L2 gene
mutation, and the tumor samples from which they were derived, can be
viewed by selecting the data set icon located on the bottom right aspect
of the inset when the mouse pointer overlays any highlighted sample(s).
B) Selected data types within the underlying data from the TCGA UCEC
and COSMIC datasets that correspond to the highlighted NFE2L2
mutations in Figure S1A. The data has been ranked first by source, then
by position at which the alteration is localized within the protein. For
non-substitution mutations, the amino at which the alteration occurs is
noted as the “position”.
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